PMID- 35362702
OWN - NLM
STAT- MEDLINE
DCOM- 20220405
LR  - 20220405
IS  - 0039-1735 (Print)
IS  - 0039-1735 (Linking)
VI  - 101
IP  - 2
DP  - 2022
TI  - [Clinical efficacy of hydroxyapatite and tricalcium phosphate modified with 
      hyaluronic acid in the treatment of patients with periimplantitis].
PG  - 42-46
LID - 10.17116/stomat202210102142 [doi]
AB  - THE AIM OF THE STUDY: Was to assess the effectiveness of the use of 
      hydroxyapatite (HAP) and tricalcium phosphate (TCF) modified with hyaluronic acid 
      in the treatment of patients with periimplantitis. MATERIALS AND METHODS: 
      Clinical studies were conducted in 128 patients (44% male and 56% female) aged up 
      to 55 years, who sought dental care with the main diagnosis of periimplant 
      mucositis and periimplantitis. To compare the features of osseointegration of 
      dental implants under bone remodeling three groups of patients were formed: one 
      control and 2 main ones. In the control group the wound was managed under a blood 
      clot, in the first main group HAP and TCF and in the second main group HAP and 
      TCF modified with hyaluronic acid were used. X-ray examination was performed in 
      various modes. Clinical assessment of implant stability in the operated area was 
      carried out using subjective (percussion and palpation method) and objective 
      method of frequency resonance analysis using the Osstell ISQ device calculating 
      the stability coefficient of the dental implant (SCDI). RESULTS: 12 months after 
      the periimplant zone remodeling procedure the bone resorption rates surrounding 
      the implant were statistically significantly the lowest in the second main group 
      (0.682+/-0.006 mm, p<0.001) compared with the values in the control and first main 
      groups (1.626+/-0.022 and 1.025+/-0.034 mm, respectively). In the former groups bone 
      resorption continued to progress during the observation period. In patients of 
      the second main group, the average values of the SCDI for all study periods were 
      68.97+/-1.09 units which turned out to be the highest indicator and significantly 
      differed from the values of other observation groups (p<0.05), which may be due 
      to a tighter fit of the implants to the surface of the newly formed bone tissue. 
      CONCLUSION: The results of the study 12 months after the periimplant zone 
      remodeling operation procedure prove the efficacy of HAP and TCF modified with 
      hyaluronic acid for the treatment of patients with periimplantitis.
FAU - Garunov, M M
AU  - Garunov MM
AUID- ORCID: 0000-0003-0563-0741
AD  - Peoples' Friendship University of Russia, Moscow, Russia.
FAU - Grigoriyants, L A
AU  - Grigoriyants LA
AUID- ORCID: 0000-0003-3226-3641
AD  - Peoples' Friendship University of Russia, Moscow, Russia.
FAU - Stepanov, A G
AU  - Stepanov AG
AUID- ORCID: 0000-0002-6543-0998
AD  - Peoples' Friendship University of Russia, Moscow, Russia.
FAU - Apresyan, S V
AU  - Apresyan SV
AUID- ORCID: 0000-0002-3281-707X
AD  - Peoples' Friendship University of Russia, Moscow, Russia.
FAU - Simonyan, D V
AU  - Simonyan DV
AUID- ORCID: 0000-0001-8826-7428
AD  - Peoples' Friendship University of Russia, Moscow, Russia.
LA  - rus
PT  - Journal Article
TT  - Klinicheskaya effektivnost' primeneniya gidroksiapatita i trikal'tsiifosfata, 
      modifitsirovannykh gialuronovoi kislotoi v lechenii patsientov s 
      periimplantitami.
PL  - Russia (Federation)
TA  - Stomatologiia (Mosk)
JT  - Stomatologiia
JID - 0412072
RN  - 0 (Calcium Phosphates)
RN  - 0 (Dental Implants)
RN  - 9004-61-9 (Hyaluronic Acid)
RN  - 91D9GV0Z28 (Durapatite)
RN  - K4C08XP666 (tricalcium phosphate)
SB  - IM
MH  - Aged
MH  - Calcium Phosphates
MH  - *Dental Implants/adverse effects
MH  - Durapatite/therapeutic use
MH  - Female
MH  - Humans
MH  - Hyaluronic Acid/therapeutic use
MH  - Male
MH  - *Peri-Implantitis/diagnostic imaging/drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - hyaluronic acid
OT  - hydroxyapatite
OT  - periimplant mucositis
OT  - periimplantitis
OT  - tricalcium phosphate
EDAT- 2022/04/02 06:00
MHDA- 2022/04/06 06:00
CRDT- 2022/04/01 10:42
PHST- 2022/04/01 10:42 [entrez]
PHST- 2022/04/02 06:00 [pubmed]
PHST- 2022/04/06 06:00 [medline]
AID - 10.17116/stomat202210102142 [doi]
PST - ppublish
SO  - Stomatologiia (Mosk). 2022;101(2):42-46. doi: 10.17116/stomat202210102142.